Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
NSCLC Guideline Updates 2025 | articles
This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for the same patient population, as well as additional non–small cell lung cancer (NSCLC) indications.
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Colon Cancer Recurrence Risk Nearly Gone After 6 Years, Study Reveals
3
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
4
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
5
